Novo co-led a second tranche that lifted Metagenomi’s series B round to $275m while crypto payment technology provider Wyre is shutting after a $1.5bn acquisition fell through.
M&A
Pharmaceutical firm Moderna has agreed to pay $85m to acquire OriCiro Genomics, a Japan-based developer of cell-free synthesis technology, allowing trading group Itochu and pharmaceutical company Asahi Kasei to exit. Coprorate venturing unit Itochu Technology Ventures took part in a $7.3m series B round in mid-2021 that increased the total raised by OriCiro to $10.9m, before Ashai Kahei added an undisclosed sum in June 2022.
Business closure
Wyre, the US-based crypto-fiat payment technology developer backed by corporates Kraken, OK Group, China 9fBank and Baofoo, is ceasing operations, the San Francisco Standard has reported. Digital payment platform developer Bolt cancelled its planned $1.5bn acquisition of the company in September 2022. Wyre had reportedly raised about $55m in funding.
Funding
| Company | Company description | Sector | Country | Round | Round size($m) | Deal date | Investors |
|---|---|---|---|---|---|---|---|
| Metagenomi | Genetic medicine developer | Healthcare | US | B | 275 (updated) | 05/01/2023 | Novo (Novo Ventures) (co-lead), Bristol Myers Squibb, Moderna, Bayer (Leaps by Bayer); Catalio Capital Management (co-lead), SymBiosis (co-lead), Farallon Capital Management, PFM Health Sciences, Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital, Marshall Wace, RA Capital Management, Humboldt Fund |
| Ganymed Robotics | Orthopaedic computer vision software developer | Healthcare | France | B | 37.9 (updated) | 04/01/2023 | BNP Paribas (BNP Paribas Développement), Credit Mutuel (Crédit Mutuel Innovation); Fund of the European Innovation Council (Accelerator Program), Cap Horn, BPIfrance, Cathay Capital (Cathay Health), Eurazeo (Kurma Partners) |
| Mantra Bio | Exosome therapeutics developer | Healthcare | US | A | 34 (updated) | 04/01/2023 | Samsung (Samsung Securities), Illumina; 8VC, Viking Global Investors, BoxGroup, Allen & Company |
| Onc.AI | Immuno-oncology-focused clinical management tool provider | Healthcare | US | A | 25 | 05/01/2023 | MassMutual (co-lead), GSK (Action Potential Venture Capital) (co-lead), Blue Cross Blue Shield Association (Blue Venture Fund); Life Extension Ventures, Accomplice, Digitalis Ventures, KdT Ventures |
| Citrine Infromatics | Provider of chemical product development software | Industrial | US | C | 16 | 04/01/2023 | Sumitomo (Presidio Ventures), Far Eastern Group (Drive Catalyst), Capgemini/ISAI (ISAI Cap Venture); Prelude Ventures (co-lead), Innovation Endeavors (co-lead), Alumni Ventures |
| Actimed Therapeutics | Developer of treatments for muscle wasting disorders | Healthcare | UK | Seed | 12 | 04/01/2023 | Mankind Pharma, undisclosed others |
| Arincare | Online pharmacy operator | Healthcare | Thailand | B | 4 | 05/01/2023 | PTGenergy (Max Ventures), Chularat Hospital Group |
| Fixposition | Autonomous navigation technology developer | IT | Switzerland | N/A | N/A | 04/01/2023 | Segway-Ninebot |
| iBody | Developer of monoclonal antibody discovery technology | Healthcare | Japan | N/A | N/A | 05/01/2023 | Tauns |
